Glenmark Pharmaceuticals’ arm gets USFDA’s nod for Fluticasone Propionate Inhalation Aerosol

04 Mar 2026 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (USFDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation.

Glenmark’s Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation has been determined by the FDA to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), FloVent HFA Inhalation Aerosol, 44 mcg of GlaxoSmithKline Intellectual Property.  Glenmark has been granted a Competitive Generic Therapy (CGT) designation for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation and is the ‘first approved applicant’ as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Glenmark is eligible for 180 days of CGT exclusivity upon commercialization.

Glenmark’s Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026. The approval further strengthens Glenmark’s respiratory portfolio in the U.S. and underscores its commitment to expanding access to quality inhalation therapies.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2110.20 70.10 (3.44%)
05-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.90
Dr. Reddys Lab 1313.05
Cipla 1326.00
Zydus Lifesciences 914.45
Lupin 2332.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×